Prognostic significance of erythropoietin expression in human renal cell carcinoma

BJU International

Volumn 100, Issue 2, 2007, Pages 291-294

  Michael, Agniezka ^a   Politi, Ekaterini ^c   Havranek, Erik ^a   Corbishley, Catherine ^b   Karapanagiotou, Lena ^c   Anderson, Chris ^b   Relph, Kate ^a   Syrigos, Konstantinos N ^c   Pandha, Hardev ^a  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b ST GEORGE'S UNIVERSITY OF LONDON   (United Kingdom)

^c SOTIRIA GENERAL HOSPITAL   (Greece)

Author keywords

Erythropoietin; Marker; Prognosis; RCC; Survival

Indexed keywords

CYTOKINE; ERYTHROPOIETIN; FORMALDEHYDE; PARAFFIN; VON HIPPEL LINDAU PROTEIN;

ADULT; AGED; ARTICLE; CANCER ADJUVANT THERAPY; CANCER PATIENT; CENTRAL NERVOUS SYSTEM; CHI SQUARE TEST; CLEAR CELL CARCINOMA; CONFIDENCE INTERVAL; CORRELATION FUNCTION; CYTOPLASM; ENDOTHELIUM CELL; ERYTHROCYTE; ERYTHROPOIESIS; FEMALE; HAZARD ASSESSMENT; HAZARD RATIO; HIGH RISK PATIENT; HUMAN; HUMAN CELL; HUMAN TISSUE; KIDNEY CARCINOMA; LIVER; MAJOR CLINICAL STUDY; MALE; NEPHRECTOMY; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; PROTEIN FUNCTION; REGULATORY MECHANISM; RETROSPECTIVE STUDY; SAMPLE; SOLID TUMOR; STAINING; STUDENT T TEST; UNIVARIATE ANALYSIS; UTERUS; VASCULAR ENDOTHELIUM;

ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, RENAL CELL; ERYTHROPOIETIN; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; KIDNEY NEOPLASMS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEPHRECTOMY; PROGNOSIS; RETROSPECTIVE STUDIES; SURVIVAL ANALYSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 34447132491     PISSN: 14644096     EISSN: 1464410X     Source Type: Journal    
DOI: 10.1111/j.1464-410X.2007.06978.x     Document Type: Article

References (27)

1. Lacombe C, Mayeux P. The molecular biology of erythropoietin. Nephrol Dial Transplant 1999 14 (Suppl. 2 22 8
2. Farrell F, Lee A. The erythropoietin receptor and its expression in tumor cells and other tissues. Oncologist 2004 9 (Suppl. 5 18 30
3. Mulcahy L. The erythropoietin receptor. Semin Oncol 2001 28 (2 Suppl. 8 19 23
4. Richmond TD, Chohan M, Barber DL. Turning cells red: signal transduction mediated by erythropoietin. Trens Cell Biol 2005 March 15 : 146 55
5. Henke M, Laszig R, Rube C et al. Erythropoietin to treat head and neck cancer patients with anaemia undergoing radiotherapy: randomised, double-blind, placebo-controlled trial. Lancet 2003 362 : 1255 60
6. MRC. Human Tissue and Biological Samples for use in Research - Operational and Ethical guidelines. 2001 Available at http://www.mrc.ac.uk/ Utilities/Documentrecord/index.htm?d=MRC002420 Accessed 15 March 2007
7. Rosti V, Pedrazzoli P, Ponchio L et al. Effect of recombinant human erythropoietin on hematopoietic and non-hematopoietic malignant cell growth in vitro. Haematologica 1993 78 : 208 12
8. Selzer E, Wacheck V, Kodym R et al. Erythropoietin receptor expression in human melanoma cells. Melanoma Res 2000 10 : 421 6
9. Westphal G, Niederberger E, Blum C et al. Erythropoietin and G-CSF receptors in human tumor cells: expression and aspects regarding functionality. Tumori 2002 88 : 150 9
10. Westenfelder C, Biddle DL, Baranowski RL. Human, rat, and mouse kidney cells express functional erythropoietin receptors. Kidney Int 1999 55 : 808 20
11. Westenfelder C, Baranowski RL. Erythropoietin stimulates proliferation of human renal carcinoma cells. Kidney Int 2000 58 : 647 57
12. Medeiros LJ, Gelb AB, Weiss LM. Renal cell carcinoma. Prognostic significance of morphologic parameters in 121 cases. Cancer 1988 61 : 1639 51
13. Thrasher JB, Paulson DF. Prognostic factors in renal cancer. Urol Clin North Am 1993 20 : 247 62
14. Roosen JU, Engel U, Jensen RH, Kvist E, Schou G. Renal cell carcinoma: prognostic factors. Br J Urol 1994 74 : 160 4
15. Bretheau D, Lechevallier E, de Fromont M, Sault MC, Rampal M, Coulange C. Prognostic value of nuclear grade of renal cell carcinoma. Cancer 1995 76 : 2543 9
16. Goncalves PD, Srougi M, Dall'lio MF, Leite KR, Ortiz V, Hering F. Low clinical stage renal cell carcinoma: relevance of microvascular tumor invasion as a prognostic parameter. J Urol 2004 172 : 470 4
17. Acs G, Acs P, Beckwith SM et al. Erythropoietin and erythropoietin receptor expression in human cancer. Cancer Res 2001 61 : 3561 5
18. Arcasoy MO, Amin K, Vollmer RT, Jiang X, Demark-Wahnefried W, Haroon ZA. Erythropoietin and erythropoietin receptor expression in human prostate cancer. Mod Pathol 2005 18 : 421 30
19. Arcasoy MO, Amin K, Chou SC, Haroon ZA, Varia M, Raleigh JA. Erythropoietin and erythropoietin receptor expression in head and neck cancer: relationship to tumor hypoxia. Clin Cancer Res 2005 11 : 20 7
20. Gnarra JR, Tory K, Weng Y et al. Mutations of the VHL tumour suppressor gene in renal carcinoma. Nat Genet 1994 7 : 85 90
21. Latif F, Tory K, Gnarra J et al. Identification of the von Hippel-Lindau disease tumor suppressor gene. Science 1993 260 : 1317 20
22. Blanchard KL, Acquaviva AM, Galson DL, Bunn HF. Hypoxic induction of the human erythropoietin gene: cooperation between the promoter and enhancer, each of which contains steroid receptor response elements. Mol Cell Biol 1992 12 : 5373 85
23. Guillemin K, Krasnow MA. The hypoxic response: huffing HIFing. Cell 1997 89 : 9 12
24. Yang JC, Haworth L, Sherry RM et al. A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. N Engl J Med 2003 349 : 427 34
25. Motzer RJ, Michaelson MD, Redman BG et al. Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma. J Clin Oncol 2006 24 : 16 24
26. Ratain MJ, Eisen T, Stadler WM et al. Phase II placebo-controlled randomized discontinuation trial of sorafenib in patients with metastatic renal cell carcinoma. J Clin Oncol 2006 24 : 2505 12
27. Song H, Wang R, Wang S, Lin J. A low molecular weight compound discovered through virtual database screening inhibits Stat3 function in breast cancer cells. PNAS 2005 102 : 4700 5